Home
Live Updates
Combination Obicetrapib plus Ezetimibe Shows Promise for Dyslipidemia in Phase 2 Trial : comparemela.com
Combination Obicetrapib plus Ezetimibe Shows Promise for Dyslipidemia in Phase 2 Trial
New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.
Related Keywords
John Kastelein ,
Christiem Ballantyne ,
York Heart Association Functional Classification Class ,
National Lipid Association ,
Newamsterdam Pharma Company ,
Baylor College Of Medicine ,
Cardiovascular Research ,
Baylor College Of Medicine Christie Ballantyne ,
Baylor College ,
Christie Ballantyne ,
Scientific Sessions ,
Consensus Decision Pathway ,
comparemela.com © 2020. All Rights Reserved.